Plasma insulin is required for the increase in plasma angiopoietin-like protein 8 in response to nutrient ingestion.
ANGPTL8
glucose
insulin
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
28
02
2023
received:
16
10
2022
accepted:
17
03
2023
medline:
4
9
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
Plasma levels of angiopoietin-like protein 8 (ANGPTL8) are regulated by feeding and they increase following glucose ingestion. Because both plasma glucose and insulin increase following food ingestion, we aimed to determine whether the increase in plasma insulin and glucose or both are responsible for the increase in ANGPTL8 levels. ANGPTL8 levels were measured in 30 subjects, 14 with impaired fasting glucose (IFG), and 16 with normal fasting glucose (NFG); the subjects received 75g glucose oral Glucose tolerance test (OGTT), multistep euglycaemic hyperinsulinemic clamp and hyperglycaemic clamp with pancreatic clamp. Subjects with IFG had significantly higher ANGPTL8 than NGT subjects during the fasting state (p < 0.05). During the OGTT, plasma ANGPTL8 concentration increased by 62% above the fasting level (p < 0.0001), and the increase above fasting in ANGPTL8 levels was similar in NFG and IFG individuals. During the multistep insulin clamp, there was a dose-dependent increase in plasma ANGPTL8 concentration. During the 2-step hyperglycaemic clamp, the rise in plasma glucose concentration failed to cause any change in the plasma ANGPTL8 concentration from baseline. In response to nutrient ingestion, ANGPTL8 level increased due to increased plasma insulin concentration, not to the rise in plasma glucose. The incremental increase above baseline in plasma ANGLPTL8 during OGTT was comparable between people with normal glucose tolerance and IFG.
Sections du résumé
BACKGROUND
Plasma levels of angiopoietin-like protein 8 (ANGPTL8) are regulated by feeding and they increase following glucose ingestion. Because both plasma glucose and insulin increase following food ingestion, we aimed to determine whether the increase in plasma insulin and glucose or both are responsible for the increase in ANGPTL8 levels.
METHODS
ANGPTL8 levels were measured in 30 subjects, 14 with impaired fasting glucose (IFG), and 16 with normal fasting glucose (NFG); the subjects received 75g glucose oral Glucose tolerance test (OGTT), multistep euglycaemic hyperinsulinemic clamp and hyperglycaemic clamp with pancreatic clamp.
RESULTS
Subjects with IFG had significantly higher ANGPTL8 than NGT subjects during the fasting state (p < 0.05). During the OGTT, plasma ANGPTL8 concentration increased by 62% above the fasting level (p < 0.0001), and the increase above fasting in ANGPTL8 levels was similar in NFG and IFG individuals. During the multistep insulin clamp, there was a dose-dependent increase in plasma ANGPTL8 concentration. During the 2-step hyperglycaemic clamp, the rise in plasma glucose concentration failed to cause any change in the plasma ANGPTL8 concentration from baseline.
CONCLUSIONS
In response to nutrient ingestion, ANGPTL8 level increased due to increased plasma insulin concentration, not to the rise in plasma glucose. The incremental increase above baseline in plasma ANGLPTL8 during OGTT was comparable between people with normal glucose tolerance and IFG.
Substances chimiques
Blood Glucose
0
Angiopoietin-Like Protein 8
0
Insulin
0
Glucose
IY9XDZ35W2
Insulin, Regular, Human
0
ANGPTL8 protein, human
0
Peptide Hormones
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3643Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Kindel T, Lee DM, Tso P. The mechanism of the formation and secretion of chylomicrons. Atheroscler Suppl. 2010;11(1):11-16. https://doi.org/10.1016/j.atherosclerosissup.2010.03.003
Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med. 2014;52(12):1695-1727. https://doi.org/10.1515/cclm-2013-0358
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150-159. https://doi.org/10.1038/ncpendmet1066
Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129(9):999-1008. https://doi.org/10.1161/circulationaha.113.002529
Scicali R, Giral P, D'Erasmo L, et al. High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. Diabetes Metab Res Rev. 2021;37(2):e3367. https://doi.org/10.1002/dmrr.3367
Sprong H, van der Sluijs P, van Meer G. How proteins move lipids and lipids move proteins. Nat Rev Mol Cell Biol. 2001;2(7):504-513. https://doi.org/10.1038/35080071
Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet. 2009;10(2):109-121. https://doi.org/10.1038/nrg2481
Hu H, Sun W, Yu S, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014;37(10):2718-2722. https://doi.org/10.2337/dc14-0602
Abu-Farha M, Abubaker J, Al-Khairi I, et al. Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep. 2015;5(1):10949. https://doi.org/10.1038/srep10949
Abu-Farha M, Abubaker J, Al-Khairi I, et al. Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):25. https://doi.org/10.1186/s12933-016-0346-0
Abu-Farha M, Abubaker J, Tuomilehto J. ANGPTL8 (betatrophin) role in diabetes and metabolic diseases. Diabetes/Metabol Res Rev. 2017
Hu W, Shao X, Guo D, et al. Relationship of serum betatrophin with nonalcoholic fatty liver in a Chinese population. PLoS One. 2017;12(1):e0170758. https://doi.org/10.1371/journal.pone.0170758
Sonmez A, Dogru T, Ercin CN, et al. Betatrophin levels are related to the early histological findings in nonalcoholic fatty liver disease. Metabolites. 2021;11(7):425. https://doi.org/10.3390/metabo11070425
Altun O, Dikker O, Arman Y, et al. Serum Angiopoietin-like peptide 4 levels in patients with hepatic steatosis. Cytokine. 2018;111:496-499. https://doi.org/10.1016/j.cyto.2018.05.030
Abu Farha RK, Alzoubi KH, Khabour OF, Alfaqih MA. Exploring perception and hesitancy toward COVID-19 vaccine: a study from Jordan. Hum Vaccin Immunother. 2021;17(8):2415-2420. https://doi.org/10.1080/21645515.2021.1888633
Wang Y, Quagliarini F, Gusarova V, et al. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA. 2013;110(40):16109-16114. https://doi.org/10.1073/pnas.1315292110
Chen YQ, Pottanat TG, Siegel RW, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids. J Lipid Res. 2020;61(8):1203-1220. https://doi.org/10.1194/jlr.ra120000781
Chen YQ, Pottanat TG, Zhen EY, et al. ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. J Lipid Res. 2021;62:100068. https://doi.org/10.1016/j.jlr.2021.100068
Balasubramaniam D, Schroeder O, Russell AM, et al. An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif. J Lipid Res. 2022;63(5):100198. https://doi.org/10.1016/j.jlr.2022.100198
Zhang R. The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking. Open Biol. 2016;6(4):150272. https://doi.org/10.1098/rsob.150272
Zhang R, Zhang K. An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues. Prog Lipid Res. 2022;85:101140. https://doi.org/10.1016/j.plipres.2021.101140
Haller JF, Mintah IJ, Shihanian LM, et al. ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance. J Lipid Res. 2017;58(6):1166-1173. https://doi.org/10.1194/jlr.m075689
Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. Nat Rev Endocrinol. 2017;13(12):731-739. https://doi.org/10.1038/nrendo.2017.119
Koster A, Chao YB, Mosior M, et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology. 2005;146(11):4943-4950. https://doi.org/10.1210/en.2005-0476
Abu-Farha M, Ghosh A, Al-Khairi I, Madiraju SRM, Abubaker J, Prentki M. The multi-faces of Angptl8 in health and disease: novel functions beyond lipoprotein lipase modulation. Prog Lipid Res. 2020;80:101067. https://doi.org/10.1016/j.plipres.2020.101067
Shang R, Rodrigues B. Lipoprotein lipase and its delivery of fatty acids to the heart. Biomolecules. 2021;11(7):1016. https://doi.org/10.3390/biom11071016
Pulinilkunnil T, Abrahani A, Varghese J, et al. Evidence for rapid ‘metabolic switching’ through lipoprotein lipase occupation of endothelial-binding sites. J Mol Cell Cardiol. 2003;35(9):1093-1103. https://doi.org/10.1016/s0022-2828(03)00205-0
Huang Y, Li X, Wang M, et al. Lipoprotein lipase links vitamin D, insulin resistance, and type 2 diabetes: a cross-sectional epidemiological study. Cardiovasc Diabetol. 2013;12(1):17. https://doi.org/10.1186/1475-2840-12-17
Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012;303(3):E334-E351. https://doi.org/10.1152/ajpendo.00084.2012
Zhang L, Shannon CE, Bakewell TM, Abdul-Ghani MA, Fourcaudot M, Norton L. Regulation of ANGPTL8 in liver and adipose tissue by nutritional and hormonal signals and its effect on glucose homeostasis in mice. Am J Physiol Endocrinol Metab. 2020;318(5):E613-E624. https://doi.org/10.1152/ajpendo.00339.2019
Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 2006;29(5):1130-1139. https://doi.org/10.2337/dc05-2179
Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55(5):1430-1435. https://doi.org/10.2337/db05-1200
Nidhina Haridas PA, Soronen J, Sadevirta S, et al. Regulation of angiopoietin-like proteins (ANGPTLs) 3 and 8 by insulin. J Clin Endocrinol Metab. 2015;100(10):E1299-E1307. https://doi.org/10.1210/jc.2015-1254
Chi X, Britt EC, Shows HW, et al. ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase. Mol Metab. 2017;6(10):1137-1149. https://doi.org/10.1016/j.molmet.2017.06.014
Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109(48):19751-19756. https://doi.org/10.1073/pnas.1217552109
Kovrov O, Kristensen KK, Larsson E, Ploug M, Olivecrona G. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity. J Lipid Res. 2019;60(4):783-793. https://doi.org/10.1194/jlr.m088807
Chen YQ, Pottanat TG, Siegel RW, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids[S]. JLR (J Lipid Res). 2020;61(8):1203-1220. https://doi.org/10.1194/jlr.ra120000781